SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
(Name of Registrant)
IDA Business Park
Bray, County Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Registration Statements on
Form F-3 (File Nos. 333-264992, 333-267160, 333-279017 and 333-280391).
EXPLANATORY NOTE
On August 2, 2024 the Company announced preliminary second quarter 2024 revenues which are expected to fall in the $15.5-$16.0 million range, demonstrating significant growth,
versus $13.9 million in total revenues reported for the second quarter of 2023.
Additionally, the Company also announced entry into a distribution agreement in the United Kingdom (UK) with MedScience, an established distributor that is a subsidiary of the
privately held Pharmed Group, a leading healthcare services provider across UK and Ireland. A copy of the press release is filed herewith as Exhibit 99.1.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
| |
TRINITY BIOTECH PLC
|
|
| |
|
Trinity Biotech plc
|
|
| |
|
(Registrant)
|
|
| |
|
|
|
| |
By:
|
/s/ John Gillard
|
|
| |
|
John Gillard
|
|
| |
|
Chief Executive Officer
|
|
Date: August 7, 2024
Exhibit 99.1
| Contact: |
Trinity Biotech plc |
LifeSci Partners, LLC |
|
Micheal Roche |
Eric Ribner |
|
(353)-1-2769800
|
(1)-646-751-4363 |
|
|
investorrelations@trinitybiotech.com |
|
|
|
|
|
RedChip Companies Inc. |
|
|
Dave Gentry, CEO
|
|
|
(1)-407-644-4256
|
|
|
TRIB@redchip.com |
Trinity Biotech Provides Preliminary Second Quarter 2024 Update
and Enters into UK Distribution Agreement with MedScience
-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double
digit percentage year over year growth-
-Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1
on annualized run-rate revenues of approximately $75 million by Q2 2025-
-Entered into MedScience distribution agreement in UK effective as of August 1, 2024 which
encompasses clinical chemistry, infectious disease, and autoimmune products-
DUBLIN, Ireland (August 2, 2024) -Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions,
including wearable biosensors, today announces preliminary second quarter 2024 revenues which are expected to fall in the $15.5-$16.0 million range, demonstrating significant growth, versus $13.9 million in total revenues reported for the second
quarter of 2023. Gross margin percentage is expected to be broadly in line with that reported for the second quarter of 2023. Additionally, Trinity also announces entry into a distribution agreement in the United Kingdom (UK) with MedScience, an
established distributor that is a subsidiary of the privately held Pharmed Group, a leading healthcare services provider across UK and Ireland. The distribution agreement encompasses Trinity Biotech’s clinical chemistry, infectious disease, and
autoimmune products in the UK and is effective as of August 1, 2024.
Trinity Biotech President and Chief Executive Officer, Mr. John Gillard, stated, “Our robust year-over-year revenue growth is a testament to the initiatives we are taking to grow product sales from our new HIV screening
product, TrinScreen HIV. We plan to issue our full second quarter 2024 earnings report in mid-August to provide an update on our full business activity including our Comprehensive Transformation Plan and our initiatives to advance our continuous
glucose monitor (CGM) program. Additionally, we are excited to partner with MedScience, a well-known distributor in their focus markets with comprehensive geographic coverage within the UK. Its large, technically trained and experienced sales
organization will enable Trinity Biotech to significantly grow its presence in the UK market across our clinical chemistry, infectious disease, and autoimmune product portfolios and further support the growth of our existing business lines and our
stated financial objectives.”
1 Earnings before interest, tax, depreciation, amortisation, share based payments from continuing operations – also excludes impairment charges and one-off items.
MedScience Chief Commercial Officer, Mr. John Gannon further added, “We are delighted with the partnership agreement with Trinity Biotech. We have long been familiar with Trinity Biotech, their expertise, and product
range, and we are looking forward to developing a long and successful relationship between our companies.”
Trinity Biotech continues to reiterate its financial guidance to achieve approximately $20 million of annualized run-rate EBITDASO2 on annualized run-rate revenues of approximately $75 million by second quarter
2025.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to
statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech
claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar
import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of Waveform,
our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s
distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on
suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of
defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of
infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December
31, 2023 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake
and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures
and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor
assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of
Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further
information, please see the Company's website: www.trinitybiotech.com.
About MedScience Distribution
MedScience, part of the Pharmed Group, is a leading provider of high-quality medical and scientific equipment, consumables, and servicing across the UK. Our exclusive distribution agreements with leading global
manufacturers ensure we deliver state-of-the-art products to laboratories, medical, and scientific service providers. Proudly serving public and private hospitals, primary care centres, community diagnostic hubs, pharmaceutical companies, academia, and
private industries. Our purpose-built headquarters in Banbury, Oxfordshire, offer modern offices, fully serviced UK based warehousing, and in-house servicing team, ideally located for major routes around the country. MedScience is committed to
providing the best products, exceptional service, and comprehensive support to meet the evolving needs of our customers.
2 Earnings before interest, tax, depreciation, amortisation, share based payments from continuing operations – also excludes impairment charges and one-off items.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
